A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli

Vaccine

Volumn 30, Issue 32, 2012, Pages 4800-4806

  Zeng, Weiguang ^a   Azzopardi, Kristy ^a,b   Hocking, Dianna ^a,b   Wong, Chinn Yi ^a   Robevska, Gorjana ^a   Tauschek, Marija ^a,b   Robins Browne, Roy M ^a,b   Jackson, David C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Diarrhea; Enterotoxigenic E. coli; ETEC; Heat stable enterotoxin; Lipopeptide; Synthetic vaccines

Indexed keywords

[2,3 BIS(PALMITOYLOXY)PROPYL]CYSTEINE; CYSTEINE; EPITOPE; ESCHERICHIA COLI ENTEROTOXIN; LIPOPEPTIDE; NEUTRALIZING ANTIBODY; OXIME; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ENTEROTOXIGENIC ESCHERICHIA COLI; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; MUCOSA; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; BACTERIAL TOXINS; ENTEROTOXIGENIC ESCHERICHIA COLI; ENTEROTOXINS; EPITOPES, T-LYMPHOCYTE; ESCHERICHIA COLI VACCINES; FEMALE; LIPOPEPTIDES; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; OXIMES; TOLL-LIKE RECEPTOR 2; VACCINES, SYNTHETIC;

EID: 84862529920     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.017     Document Type: Article

References (38)

1. Walker R.I., Steele D., Aguado T. Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease. Vaccine 2007, 25:2545-2566.
2. The World Health Organization. Enterotoxigenic Escherichia coli (ETEC). http://wwwwhoint/vaccine_research/diseases/diarrhoeal/en/index4html.
3. Al-Abri S.S., Beeching N.J., Nye F.J. Traveller's diarrhoea. Lancet Infect Dis 2005, 5:349-360.
4. Field M. Mechanisms of action of cholera and Escherichia coli enterotoxins. Am J Clin Nutr 1979, 32:189-196.
5. Kennedy D.J., Greenberg R.N., Dunn J.A., Abernathy R., Ryerse J.S., Guerrant R.L. Effects of Escherichia coli heat-stable enterotoxin STb on intestines of mice, rats, rabbits, and piglets. Infect Immun 1984, 46:639-643.
6. Sanchez J., Holmgren J. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr Opin Immunol 2005, 17:388-398.
7. Boedeker E.C. Gastrointestinal infections: an overview. Curr Opin Gastroenterol 2004, 20:1-2.
8. Evans D.J., Ruiz-Palacios G., Evans D.E., DuPont H.L., Pickering L.K., Olarte J. Humoral immune response to the heat-labile enterotoxin of Escherichia coli in naturally acquired diarrhea and antitoxin determination by passive immune hemolysis. Infect Immun 1977, 16:781-788.
9. Frech S.A., Dupont H.L., Bourgeois A.L., McKenzie R., Belkind-Gerson J., Figueroa J.F., et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008, 371:2019-2025.
10. Levine M.M., Nalin D.R., Hoover D.L., Bergquist E.J., Hornick R.B., Young C.R. Immunity to enterotoxigenic Escherichia coli. Infect Immun 1979, 23:729-736.
11. Taxt A., Aasland R., Sommerfelt H., Nataro J., Puntervoll P. Heat-stable enterotoxin of enterotoxigenic Escherichia coli as a vaccine target. Infect Immun 2010, 78:1824-1831.
12. Nataro J.P., Kaper J.B. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998, 11:142-201.
13. Sato T., Shimonishi Y. Structural features of Escherichia coli heat-stable enterotoxin that activates membrane-associated guanylyl cyclase. J Pept Res 2004, 63:200-206.
14. Yoshimura S., Ikemura H., Watanabe H., Aimoto S., Shimonishi Y., Hara S., et al. Essential structure for full enterotoxigenic activity of heat-stable enterotoxin produced by enterotoxigenic Escherichia coli. FEBS Lett 1985, 181:138-142.
15. Klipstein F.A., Engert R.F., Clements J.D., Houghten R.A. Vaccine for enterotoxigenic Escherichia coli based on synthetic heat-stable toxin crossed-linked to the B subunit of heat-labile toxin. J Infect Dis 1983, 147:318-326.
16. Sanchez J., Svennerholm A.M., Holmgren J. Genetic fusion of a non-toxic heat-stable enterotoxin-related decapeptide antigen to cholera toxin B-subunit. FEBS Lett 1988, 241:110-114.
17. da Hora V.P., Conceicao F.R., Dellagostin O.A., Doolan D.L. Non-toxic derivatives of LT as potent adjuvants. Vaccine 2011, 29:1538-1544.
18. Aitken R., Hirst T.R. Recombinant enterotoxins as vaccines against Escherichia coli-mediated diarrhoea. Vaccine 1993, 11:227-233.
19. Batisson I. Der Vartanian M, Gaillard-Martinie B, Contrepois M. Full capacity of recombinant Escherichia coli heat-stable enterotoxin fusion proteins for extracellular secretion, antigenicity, disulfide bond formation, and activity. Infect Immun 2000, 68:4064-4074.
20. Clements J.D. Construction of a nontoxic fusion peptide for immunization against Escherichia coli strains that produce heat-labile and heat-stable enterotoxins. Infect Immun 1990, 58:1159-1166.
21. Lowenadler B., Lake M., Elmblad A., Holmgren E., Holmgren J., Karlstrom A., et al. A recombinant Escherichia coli heat-stable enterotoxin (STa) fusion protein eliciting anti-STa neutralizing antibodies. FEMS Microbiol Lett 1991, 66:271-277.
22. Zhang W., Francis D.H. Genetic fusions of heat-labile toxoid (LT) and heat-stable toxin b (STb) of porcine enterotoxigenic Escherichia coli elicit protective anti-LT and anti-STb antibodies. Clin Vaccine Immunol 2010, 17:1223-1231.
23. Klipstein F.A., Engert R.F., Clements J.D., Houghten R.A. Protection against human and porcine enterotoxigenic strains of Escherichia coli in rats immunized with a cross-linked toxoid vaccine. Infect Immun 1983, 40:924-929.
24. Svennerholm A.M., Wikstrom M., Lindblad M., Holmgren J. Monoclonal antibodies against Escherichia coli heat-stable toxin (STa) and their use in a diagnostic ST ganglioside GM1-enzyme-linked immunosorbent assay. J Clin Microbiol 1986, 24:585-590.
25. Alphs H.H., Gambhira R., Karanam B., Roberts J.N., Jagu S., Schiller J.T., et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A 2008, 105:5850-5855.
26. Day E.B., Zeng W., Doherty P.C., Jackson D.C., Kedzierska K., Turner S.J. The context of epitope presentation can influence functional quality of recalled influenza A virus-specific memory CD8+ T cells. J Immunol 2007, 179:2187-2194.
27. Deliyannis G., Kedzierska K., Lau Y.F., Zeng W., Turner S.J., Jackson D.C., et al. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur J Immunol 2006, 36:770-778.
28. Jackson D.C., Lau Y.F., Le T., Suhrbier A., Deliyannis G., Cheers C., et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A 2004, 101:15440-15445.
29. Batzloff M.R., Hartas J., Zeng W., Jackson D.C., Good M.F. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. J Infect Dis 2006, 194:325-330.
30. Baz A., Buttigieg K., Zeng W., Rizkalla M., Jackson D.C., Groves P., et al. Branched and linear lipopeptide vaccines have different effects on primary CD4(+) and CD8(+) T-cell activation but induce similar tumor-protective memory CD8(+) T-cell responses. Vaccine 2008, 26:2570-2579.
31. Zeng W., Pagnon J., Jackson D.C. The C-terminal pentapeptide of LHRH is a dominant B cell epitope with antigenic and biological function. Biopolymers 2007, 88:566.
32. Zeng W., Ghosh S., Lau Y.F., Brown L.E., Jackson D.C. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 2002, 169:4905-4912.
33. Zeng W., Gauci S., Ghosh S., Walker J., Jackson D.C. Characterisation of the antibody response to a totally synthetic immunocontraceptive peptide vaccine based on LHRH. Vaccine 2005, 23:4427-4435.
34. Zeng W., Horrocks K.J., Robevska G., Wong C.Y., Azzopardi K., Tauschek M., et al. A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building. J Biol Chem 2011, 286:12944-12951.
35. Robins-Browne R.M., Levine M.M. Effect of chlorpromazine on intestinal secretion mediated by Escherichia coli heat-stable enterotoxin and 8-Br-cyclic GMP in infant mice. Gastroenterology 1981, 80:321-326.
36. Zeng W., Eriksson E., Chua B., Grollo L., Jackson D.C. Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys. Amino Acids 2010, 39:471-480.
37. Weltzin R., Guy B., Thomas W.D., Giannasca P.J., Monath T.P. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect Immun 2000, 68:2775-2782.
38. Sanchez J., Johansson S., Lowenadler B., Svennerholm A.M., Holmgren J. Recombinant cholera toxin B subunit and gene fusion proteins for oral vaccination. Res Microbiol 1990, 141:971-979.